TCGA-CV-5443-01A-01R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- ALLOGRAFT_REJECTION+0.340
- G2M_CHECKPOINT+0.230
- MITOTIC_SPINDLE+0.210
- IL6_JAK_STAT3_SIGNALING+0.200
- SPERMATOGENESIS+0.150
- APICAL_SURFACE+0.100
- DNA_REPAIR+0.100
- IL2_STAT5_SIGNALING+0.060
- ADIPOGENESIS+0.050
Top 10 suppressed
- PROTEIN_SECRETION-0.420
- INTERFERON_ALPHA_RESPONSE-0.360
- TGF_BETA_SIGNALING-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- MYC_TARGETS_V2-0.300
- HYPOXIA-0.280
- MYOGENESIS-0.280
- ANGIOGENESIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-5248-01A-01R-2016-07 | — | — | 0.885 |
| 2 | SRR2932833 | — | — | 0.828 |
| 3 | TCGA-CR-6467-01A-11R-1873-07 | — | — | 0.828 |
| 4 | TCGA-CR-7404-01A-11R-2132-07 | — | — | 0.824 |
| 5 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.806 |
| 6 | TCGA-CN-5374-01A-01R-1436-07 | — | — | 0.793 |
| 7 | TCGA-CR-7385-01A-11R-2016-07 | — | — | 0.783 |
| 8 | TCGA-QK-A6V9-01A-11R-A34R-07 | — | — | 0.770 |
| 9 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.755 |
| 10 | SRR25617823 | — | D | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |